Protagenic Therapeutics (PTIX) Competitors $3.32 -0.20 (-5.68%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.34 +0.02 (+0.45%) As of 06/13/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PTIX vs. TSBX, CDIO, ACXP, SLXN, PRTG, OBSV, GTBP, CVM, CHRO, and APLMShould you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Turnstone Biologics (TSBX), Cardio Diagnostics (CDIO), Acurx Pharmaceuticals (ACXP), Silexion Therapeutics (SLXN), Portage Biotech (PRTG), ObsEva (OBSV), GT Biopharma (GTBP), CEL-SCI (CVM), Chromocell Therapeutics (CHRO), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry. Protagenic Therapeutics vs. Its Competitors Turnstone Biologics Cardio Diagnostics Acurx Pharmaceuticals Silexion Therapeutics Portage Biotech ObsEva GT Biopharma CEL-SCI Chromocell Therapeutics Apollomics Protagenic Therapeutics (NASDAQ:PTIX) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership. Does the media prefer PTIX or TSBX? In the previous week, Protagenic Therapeutics and Protagenic Therapeutics both had 2 articles in the media. Turnstone Biologics' average media sentiment score of 1.44 beat Protagenic Therapeutics' score of 1.43 indicating that Turnstone Biologics is being referred to more favorably in the news media. Company Overall Sentiment Protagenic Therapeutics Positive Turnstone Biologics Positive Which has more volatility and risk, PTIX or TSBX? Protagenic Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Do analysts rate PTIX or TSBX? Turnstone Biologics has a consensus target price of $0.45, suggesting a potential upside of 31.20%. Given Turnstone Biologics' stronger consensus rating and higher probable upside, analysts clearly believe Turnstone Biologics is more favorable than Protagenic Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagenic Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the MarketBeat Community prefer PTIX or TSBX? Turnstone Biologics received 4 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users. Likewise, 44.44% of users gave Turnstone Biologics an outperform vote while only 0.00% of users gave Protagenic Therapeutics an outperform vote. CompanyUnderperformOutperformProtagenic TherapeuticsOutperform VotesNo VotesUnderperform Votes1100.00% Turnstone BiologicsOutperform Votes444.44% Underperform Votes555.56% Which has preferable valuation and earnings, PTIX or TSBX? Protagenic Therapeutics has higher earnings, but lower revenue than Turnstone Biologics. Protagenic Therapeutics is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagenic TherapeuticsN/AN/A-$5M-$13.11-0.25Turnstone Biologics$19.31M0.41-$55.20M-$2.73-0.13 Do insiders & institutionals believe in PTIX or TSBX? 8.0% of Protagenic Therapeutics shares are held by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are held by institutional investors. 35.0% of Protagenic Therapeutics shares are held by insiders. Comparatively, 32.1% of Turnstone Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is PTIX or TSBX more profitable? Turnstone Biologics' return on equity of -105.99% beat Protagenic Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagenic TherapeuticsN/A -308.97% -228.73% Turnstone Biologics N/A -105.99%-87.27% SummaryTurnstone Biologics beats Protagenic Therapeutics on 12 of the 14 factors compared between the two stocks. Get Protagenic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.96M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.15%P/E Ratio-2.618.5026.7819.65Price / SalesN/A263.07404.47152.18Price / CashN/A65.8538.2534.64Price / Book4.006.526.964.59Net Income-$5M$143.48M$3.23B$248.23M7 Day Performance-8.29%-0.21%-1.22%-1.07%1 Month Performance6.41%10.62%6.34%2.60%1 Year Performance-76.98%3.63%33.05%13.51% Protagenic Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXProtagenic Therapeutics1.3166 of 5 stars$3.32-5.7%N/A-77.0%$1.96MN/A-2.612Short Interest ↓TSBXTurnstone Biologics3.2943 of 5 stars$0.37+1.4%$0.45+23.0%-87.3%$8.47M$19.31M-0.1182Positive NewsShort Interest ↓Gap DownCDIOCardio Diagnostics1.7807 of 5 stars$4.84+1.7%$60.00+1,139.7%-77.4%$8.42M$19.90K0.001Short Interest ↑ACXPAcurx Pharmaceuticals3.2222 of 5 stars$0.33-3.5%$8.00+2,288.8%-87.4%$8.15MN/A-0.313Positive NewsSLXNSilexion TherapeuticsN/A$0.93-1.2%$5.00+435.2%N/A$8.12MN/A0.00N/AUpcoming EarningsGap DownPRTGPortage Biotech1.0779 of 5 stars$7.60-9.6%N/A+22.3%$7.97MN/A-0.186Positive NewsShort Interest ↓OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150GTBPGT Biopharma2.6334 of 5 stars$3.02+12.7%$11.00+264.2%-1.7%$7.81MN/A-0.538Short Interest ↑Gap UpCVMCEL-SCI0.0781 of 5 stars$2.54+6.7%N/A-94.2%$7.70MN/A-5.2943High Trading VolumeCHROChromocell Therapeutics1.1661 of 5 stars$1.21+6.2%N/A-5.7%$7.52MN/A-0.984Short Interest ↓Gap UpAPLMApollomics1.2334 of 5 stars$6.75+3.8%N/A-68.0%$7.45M$1.22M0.0045Positive News Related Companies and Tools Related Companies Turnstone Biologics Alternatives Cardio Diagnostics Alternatives Acurx Pharmaceuticals Alternatives Silexion Therapeutics Alternatives Portage Biotech Alternatives ObsEva Alternatives GT Biopharma Alternatives CEL-SCI Alternatives Chromocell Therapeutics Alternatives Apollomics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTIX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTIX Stock Free PTIX Stock Alerts